Abstract:Recently, an astrocytic aquaporin 4-dependent drainage system, that is, the glymphatic system, has been identified in the live murine and human brain. Growing evidence suggests that glymphatic function is impaired in patients with several neurodegenerative diseases, including Alzheimer's and Parkinson's disease. As the third most common neurodegenerative disease, although animal studies have indicated that early glymphatic dysfunction is likely an important pathological mechanism underpinning amyotrophic lateral sclerosis (ALS), no available study has been conducted to thoroughly assess glymphatic function in vivo in ALS patients to date, particularly in early-stage ALS patients. Thus, using DTI analysis along the perivascular space (ALPS) index, an approximate measure of glymphatic function in vivo, we aimed to explore whether glymphatic function is impaired in early-stage ALS patients and the diagnostic performance of the ALPS index in distinguishing between early-stage ALS patients and healthy subjects. We also aimed to identify the relationships between glymphatic dysfunction and clinical disabilities and sleep problems in early-stage ALS patients. In this retrospective study, King's stage 1 ALS patients were defined as early-stage ALS patients. We enrolled 56 early-stage ALS patients and 32 age- and sex-matched healthy controls (HCs). All participants completed clinical screening, sleep assessment, and ALPS index analysis. For the sleep assessment, the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and polysomnography were used. Compared with HCs, early-stage ALS patients had a significantly lower ALPS index after family-wise error correction (p < 0.05). Moreover, receiver operating characteristic analysis showed that the area under the curve for the ALPS index was 0.792 (95% confidence interval 0.700-0.884). Partial correlation analyses showed that the ALPS index was significantly correlated with clinical disability and sleep disturbances in early-stage ALS patients. Multivariate analysis showed that sleep efficiency (r = 0.419; p = 0.002) and periodic limb movements in sleep index (r = -0.294; p = 0.017) were significant predictive factors of the ALPS index in early-stage ALS patients. In conclusion, our study continues to support an important role for glymphatic dysfunction in ALS pathology, and we provide additional insights into the early diagnostic value of glymphatic dysfunction and its correlation with sleep disturbances in vivo in early-stage ALS patients. Moreover, we suggest that early improvement of glymphatic function may be a promising strategy for slowing the neurodegenerative process in ALS. Future studies are needed to explore the diagnostic and therapeutic value of glymphatic dysfunction in individuals with presymptomatic-stage neurodegenerative diseases.

Longitudinal analysis of glymphatic function in amyotrophic lateral sclerosis and primary lateral sclerosis

Glymphatic dysfunction in patients with early-stage amyotrophic lateral sclerosis

Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis

A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS

Noninvasive neuroimaging provides evidence for deterioration of the glymphatic system in Parkinson's disease relative to essential tremor

The Association of the Glymphatic Function with Parkinson's Disease Symptoms: Neuroimaging Evidence from Longitudinal and Cross-Sectional Studies

Glymphatic dysfunction in multiple sclerosis and its association with disease pathology and disability

Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis

Multiple pathways of lipid dysregulation in amyotrophic lateral sclerosis

The Visual Pathway: A Valuable Biomarker of Disease Duration and Cognitive Function in Amyotrophic Lateral Sclerosis

Distinct Longitudinal Changes in EEG Measures Reflecting Functional Network Disruption in ALS Cognitive Phenotypes

Automated diffusion-weighted image analysis along the perivascular space index reveals glymphatic dysfunction in association with brain parenchymal lesions

Proteomic Analysis of Cerebrospinal Fluid in Amyotrophic Lateral Sclerosis

The Glymphatic System And Amyotrophic Lateral Sclerosis

The Glymphatic System as a Potential Biomarker and Therapeutic Target in Secondary Progressive Multiple Sclerosis

Mismatch between clinically defined classification of ALS stage and the burden of cerebral pathology

Direct interrogation of cortical interneuron circuits in amyotrophic lateral sclerosis

Key Molecules and Pathways Underlying Sporadic Amyotrophic Lateral Sclerosis: Integrated Analysis on Gene Expression Profiles of Motor Neurons

Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain

Glymphatic dysfunction correlates with severity of small vessel disease and cognitive impairment in cerebral amyloid angiopathy

Evaluation of glymphatic system activity using diffusion tensor image analysis along the perivascular space and amyloid PET in older adults with objectively normal cognition: a preliminary study